Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria
Main Authors: | Minna Harmanen, Tuula Klaavuniemi, Marc Sorigue, Madiha Khan, Roosa Prusila, Esa Kari, Erika Alanne, Aino Rajamäki, Kaisa Sunela, Arja Jukkola, Esa Jantunen, Juan-Manuel Sancho, Sanna Ketola, Hanne Kuitunen, Tuomas Selander, Aino Rönkä, Outi Kuittinen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-10-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000954 |
Similar Items
-
FDG‐PET/CT‐guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma
by: Aino Rajamäki, et al.
Published: (2023-01-01) -
Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors
by: Elina Kaprio, et al.
Published: (2024-01-01) -
A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors
by: Satu Tiainen, et al.
Published: (2023-12-01) -
Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas
by: Marc Sorigue, et al.
Published: (2022-12-01) -
Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study
by: Hanne K. Kuitunen, et al.
Published: (2023-02-01)